FLUORINATED 3-(2-OXO-3-(3-ARYLPROPYL)IMIDAZOLIDIN-1-YL)-3-ARYLPROPANOIC ACID DERIVATIVES

1 . A compound of formula I:

or a pharmaceutically acceptable salt or solvate thereof, wherein

X is selected from CH and N;

Y is selected from CH and N;

R 1 is C 1 -C 6 alkoxy wherein said C 1 -C 6 alkoxy is substituted with 0, 1, 2, 3, 4, or 5 fluorine atoms;

and

R 2 and R 3 are each independently selected from H and F,

or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3- or 4-membered carbocyclic or heterocyclic ring,

provided that the compound of formula I contains at least one fluorine atom.

2 . The compound of claim 1 , wherein the compound is of formula II:

or a pharmaceutically acceptable salt or solvate thereof, wherein

X is selected from CH and N;

Y is selected from CH and N;

R 1 is C 1 -C 6 alkoxy wherein said C 1 -C 6 alkoxy is substituted with 0, 1, 2, 3, 4, or 5 fluorine atoms;

and

R 2 and R 3 are each independently selected from H and F,

or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3- or 4-membered carbocyclic or heterocyclic ring,

provided that the compound of formula II contains at least one fluorine atom.

3 . The compound of claim 1 , wherein the compound is of formula III:

or a pharmaceutically acceptable salt or solvate thereof, wherein

R 1 is C 1 -C 6 alkoxy wherein said C 1 -C 6 alkoxy is substituted with 0, 1, 2, 3, 4, or 5 fluorine atoms;

and

R 2 and R 3 are each independently selected from H and F,

or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3- or 4-membered carbocyclic or heterocyclic ring,

provided that the compound of formula III contains at least one fluorine atom.

4 . The compound of claim 1 , wherein the compound is of formula IV:

or a pharmaceutically acceptable salt or solvate thereof, wherein

R 1 is C 1 -C 6 alkoxy wherein said C 1 -C 6 alkoxy is substituted with 0, 1, 2, 3, 4, or 5 fluorine atoms;

and

R 2 and R 3 are each independently selected from H and F,

or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3- or 4-membered carbocyclic or heterocyclic ring,

provided that the compound of formula IV contains at least one fluorine atom.

5 . The compound of claim 1 , wherein the compound is of formula V:

or a pharmaceutically acceptable salt or solvate thereof, wherein

R 1 is C 1 -C 6 alkoxy wherein said C 1 -C 6 alkoxy is substituted with 0, 1, 2, 3, 4, or 5 fluorine atoms;

and

R 2 and R 3 are each independently selected from H and F,

or R 2 and R 3 taken together with the carbon atom to which they are attached form a 3- or 4-membered carbocyclic or heterocyclic ring,

provided that the compound of formula V contains at least one fluorine atom.

6 . A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt or solvate thereof as in one of claim 1 and a pharmaceutical carrier, diluent, or excipient.

7 . A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt or solvate thereof as in one of claim 2 and a pharmaceutical carrier, diluent, or excipient.

8 . A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt or solvate thereof as in one of claim 3 and a pharmaceutical carrier, diluent, or excipient.

9 . A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt or solvate thereof as in one of claim 4 and a pharmaceutical carrier, diluent, or excipient.

10 . A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt or solvate thereof as in one of claim 5 and a pharmaceutical carrier, diluent, or excipient.

11 . A method of treating and/or preventing a condition, eliciting an integrin receptor antagonizing effect, inhibiting bone resorption, or treating tumor growth in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or solvate as in one of claim 1 .

12 . A method of treating and/or preventing a condition, eliciting an integrin receptor antagonizing effect, inhibiting bone resorption, or treating tumor growth in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or solvate as in one of claim 2 .

13 . A method of treating and/or preventing a condition, eliciting an integrin receptor antagonizing effect, inhibiting bone resorption, or treating tumor growth in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or solvate as in one of claim 3 .

14 . A method of treating and/or preventing a condition, eliciting an integrin receptor antagonizing effect, inhibiting bone resorption, or treating tumor growth in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or solvate as in one of claim 4 .

15 . A method of treating and/or preventing a condition, eliciting an integrin receptor antagonizing effect, inhibiting bone resorption, or treating tumor growth in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt or solvate as in one of claim 5 .

16 . A method of synthesizing a compound or a pharmaceutically acceptable salt or solvate thereof as in one of claim 1 .

17 . A method of synthesizing a compound or a pharmaceutically acceptable salt or solvate thereof as in one of claim 2 .

18 . A method of synthesizing a compound or a pharmaceutically acceptable salt or solvate thereof as in one of claim 3 .

19 . A method of synthesizing a compound or a pharmaceutically acceptable salt or solvate thereof as in one of claim 4 .

20 . A method of synthesizing a compound or a pharmaceutically acceptable salt or solvate thereof as in one of claim 5 .